Forte Biosciences (NASDAQ:FBRX – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.11), Zacks reports.
Forte Biosciences Stock Performance
NASDAQ:FBRX traded down $0.01 during midday trading on Friday, reaching $0.30. The stock had a trading volume of 276,045 shares, compared to its average volume of 19,129. Forte Biosciences has a 1-year low of $0.28 and a 1-year high of $0.91. The firm’s fifty day simple moving average is $0.52 and its 200-day simple moving average is $0.62.
Analysts Set New Price Targets
Separately, Brookline Capital Management initiated coverage on shares of Forte Biosciences in a report on Thursday, May 30th. They issued a “buy” rating and a $4.00 price objective for the company.
About Forte Biosciences
Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.
Featured Articles
- Five stocks we like better than Forte Biosciences
- Why is the Ex-Dividend Date Significant to Investors?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Insider Trading – What You Need to Know
- MarketBeat Week in Review – 8/12 – 8/16
- 3 Grocery Stocks That Are Proving They Are Still Essential
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Forte Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forte Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
